This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
The retracted studies were coauthored by a scientist who worked on an Alzheimer’s therapy in development by Cassava Sciences, a company reportedly under investigation for providing falsified data to the FDA.
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
The makers of the CRISPR-based testing platform, called miSHERLOCK, say it could enable people at home or physicians in resource-limited environments to detect SARS-CoV-2—and eventually, other pathogens.
Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.
A nascent but growing consumer market for brain-computer interface technology is driving the development of sleek new tools for decoding brain activity.
The California-based company Humm has developed a “bioelectric memory patch” to improve working memory, but some experts question the efficacy of the device.
In a small trial of deceased volunteers, a Seattle-based company called Recompose demonstrates that its method for “natural organic reduction” of a human body completely breaks down soft tissue.